ELAN
Elanco Animal Health Incorporated · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -11.1% ·
share flow -9.6% ·
net new positions -12.5%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 276.62K | $5.90M | n/a | n/a |
| Q2 2026 | 130 | +5 | 426.69M | $10.50B | +12 | −6 |
| Q1 2026 | 127 | -2 | 403.59M | $9.65B | +6 | −9 |
| Q4 2025 | 128 | +1 | 433.50M | $9.81B | +4 | −2 |
| Q3 2025 | 20 | -1 | 348.71M | $7.02B | n/a | −2 |
| Q2 2025 | 19 | +2 | 313.01M | $4.47B | +3 | −1 |
| Q1 2025 | 14 | -2 | 167.03M | $1.75B | +1 | −3 |
| Q4 2024 | 16 | -2 | 168.00M | $2.03B | n/a | −2 |
| Q3 2024 | 17 | +1 | 175.40M | $2.58B | +1 | n/a |
| Q2 2024 | 16 | n/a | 207.32M | $2.99B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 83.18M | -0.2% | $1.01B | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 51.17M | -2.7% | $619.61M | 0.5% | ▼ Trim | 3 | SEC ↗ |
| 3 | State Street Global Advisors ✦ (passive) | 10.42M | n/a | $126.21M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 8.18M | +4.0% | $99.10M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 3.99M | -0.3% | $48.36M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 6 | Norges Bank ✦ (passive) | 3.92M | +9.7% | $47.42M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 1.74M | +148.8% | $21.09M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 1.61M | -78.5% | $19.54M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 1.59M | -82.3% | $19.27M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 660.64K | -35.8% | $8.00M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 11 | T. Rowe Price ✦ | 556.47K | -81.7% | $6.74M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 477.77K | +41.0% | $5.79M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 242.43K | +22.8% | $2.90M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 14 | Marshall Wace ✦ | 167.82K | -57.9% | $2.03M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 62.77K | -86.9% | $760,108 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 26.17K | -25.9% | $316,919 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $19.71M | was 0.1% |
| Arrowstreet Capital | $377,195 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 512 holders, 543.55M shares, $11.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 40.00K sh @ 23.40 · $935,920
Officer · GC AND CORP SEC · 4.00K sh @ 23.58 · $94,273
Director · 5.00K sh @ 21.82 · $109,100
Director · 10.00K sh @ 23.68 · $236,850
Officer · EVP and CFO · 4.20K sh @ 23.08 · $96,926
Open-market sales (S)
Officer · 4.35K sh · $100,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology